Inicio>>Signaling Pathways>> GPCR/G protein>> Ras>>GGTI-286

GGTI-286

Catalog No.GC64216

GGTI-286, un inhibidor de la GGTasa I potente y permeable a las células, es 25 veces mÁs potente (IC50=2 μM) que el correspondiente éster metÍlico de FTI-276. GGTI-286 inhibe selectivamente la geranilgeranilaciÓn de Rap1A sobre la farnesilaciÓn de H-Ras en células NIH3T3 (IC50s = 2 y > 30 μM, respectivamente). GGTI-286 también inhibe potentemente la estimulaciÓn oncogénica de K-Ras4B con una IC50 de 1 μM.

Products are for research use only. Not for human use. We do not sell to patients.

GGTI-286 Chemical Structure

Cas No.: 171744-11-9

Tamaño Precio Disponibilidad Cantidad
5 mg
468,00 $
Disponible
10 mg
765,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 . GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM[1].

[1]. E C Lerner, et al. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem. 1995 Nov 10;270(45):26770-3. [2]. Naoyuki Nishiya, et al. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/β-catenin pathway. Chem Biol. 2014 Apr 24;21(4):530-540.

Reseñas

Review for GGTI-286

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GGTI-286

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.